A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.
Non-squamous Non-small Cell Lung Cancer
DRUG: apatinib docetaxel zoledronic|DRUG: docetaxel zoledronic
Progression free survival, evaluation per 2 cycles (6 weeks)
Overall survival, evaluation per 2 cycles (6 weeks)|DCR (Disease control rate), evaluation per 2 cycles (6 weeks)|ORR (Objective response rate), evaluation per 2 cycles (6 weeks)|SREs（Skeletal-related events）, measured pain, a fracture, the need for bone radiation or surgical therapy, spinal cord compression, or hypercalcemia, evaluation per 2 cycles (6 weeks)|Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, evaluation per 2 cycles (6 weeks)
The purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus docetaxel and zoledronic versus docetaxel and zoledronic alone as second line treatment for advanced non-squamous non-small cell lung cancer with bone metastases.